Hedgeye 130/30 Equity ETF (HELS)
Live price chart, market sentiment, and community perspectives for Hedgeye 130/30 Equity ETF (AMEX: HELS).
Live price chart, market sentiment, and community perspectives for Hedgeye 130/30 Equity ETF (AMEX: HELS).
On our desk, evaluating HELS comes down to the stark reality of its trading frictions. While a 0.70% expense ratio looks defensible for an active 130/30 extension strategy, a bid-ask spread floating around 153 basis points introduces massive hidden friction on every round-trip trade. Combined with an asset base hovering near $22.5 million—well below the $100M threshold required for long-term operational sustainability—it is a difficult vehicle to recommend for standard institutional mandates right now, especially given the challenging macro backdrop of tariff-driven growth scares and spiked VIX levels.
Watching the 50-day moving average and current technical indicators for HELS, the risk profile continues to flash warning signs. Trading roughly 4.7% below its MA50 of $24.85 with a negative YTD NAV return putting it near the bottom of its Long-Short Equity peer group, the strategy lacks the valuation cushion needed in a volatile market. Furthermore, the short sleeve introduces tax drag that makes it sub-optimal for standard taxable accounts, compounding the frustration of a Sharpe ratio sitting at -1.42 and a Sortino ratio at -1.55.
From a quantitative and portfolio management lens, analyzing Hedgeye's execution of the 130/30 mandate reveals a strategy under heavy pressure. Even though 11 hedge funds and large institutions held roughly $4.91M in Q1 2026, the fund's short-term track record since its December 2025 inception reflects the difficulties of bottom-up stock picking amid persistent policy uncertainty and Federal Reserve rate-cut expectations. For quants building multi-factor allocation models, the low liquidity, sub-$100K daily trading volumes, and weak alpha signals currently cap its probability of outperforming broad benchmarks in the near term.
Explore plasma cleansing, somatic organ swaps, and BCI.